All In Biotech

Drug Trial Radar · NCT07049328

HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

A Phase 1 Study of HCW9302, an IL-2 Fusion Protein, for Alopecia Areata

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Aug 16, 2025

Primary completion

Jul 16, 2027

Study completion Dec 15, 2027

Sponsor

Lead sponsor
HCW BiologicsIndustry
Sponsor type
Industry
First posted
Jul 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)

Conditions

  • Alopecia Areata(AA)

Interventions

  • HCW9302, an IL-2 fusion proteinDrug

    Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) in Subjects Receiving HCW9302 MonotherapyTime frame: 9 Weeks
  2. Designate the recommended Phase 2 dose level (RP2D) for Phase 2 study of HCW9302 in subjects with AATime frame: 9 Weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • James A. Haley Veterans' Hospital

    Tampa, Florida · Recruiting

  • Dawes Fretzin Clinical Research Group

    Indianapolis, Indiana · Recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.